Skip to Content

Invega Sustenna Approval History

Invega Sustenna (1-month paliperidone palmitate) is a long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia and schizoaffective disorder.

Development History and FDA Approval Process for Invega Sustenna

Nov 13, 2014Approval FDA Approves sNDA for Invega Sustenna (paliperidone palmitate) for Schizoaffective Disorder
Aug  3, 2009Approval FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.